+

WO2009002811A3 - Compositions thérapeutique plaquette et procédés - Google Patents

Compositions thérapeutique plaquette et procédés Download PDF

Info

Publication number
WO2009002811A3
WO2009002811A3 PCT/US2008/067592 US2008067592W WO2009002811A3 WO 2009002811 A3 WO2009002811 A3 WO 2009002811A3 US 2008067592 W US2008067592 W US 2008067592W WO 2009002811 A3 WO2009002811 A3 WO 2009002811A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
angiogenesis
platelets
regulating
compositions
Prior art date
Application number
PCT/US2008/067592
Other languages
English (en)
Other versions
WO2009002811A2 (fr
Inventor
Dennis Orgill
Giorgio Pietramaggiori
Giannoula Klement
David Cervi
Judah Folkman
Original Assignee
Childrens Medical Center
Brigham & Womens Hospital
Dennis Orgill
Giorgio Pietramaggiori
Giannoula Klement
David Cervi
Judah Folkman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center, Brigham & Womens Hospital, Dennis Orgill, Giorgio Pietramaggiori, Giannoula Klement, David Cervi, Judah Folkman filed Critical Childrens Medical Center
Publication of WO2009002811A2 publication Critical patent/WO2009002811A2/fr
Publication of WO2009002811A3 publication Critical patent/WO2009002811A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/008—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/64—Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des procédés et des compositions destinés à l'administration thérapeutique de facteurs de régulation de l'angiogenèse à des sites in vivo les nécessitant. Les procédés et les compositions portent de manière générale sur l'utilisation de plaquettes portant un ou plusieurs facteurs de régulation exogènes de l'angiogenèse. Selon un aspect, l'invention concerne des procédés d'administration d'un facteur de régulation de l'angiogenèse, le procédé consistant à mettre en contact un tissu avec une composition contenant des plaquettes isolées qui renferment un facteur de régulation exogène de l'angiogenèse. Les procédés peuvent notamment être utilisés pour accélérer la cicatrisation de plaies, ou, dans une variante, pour inhiber la croissance tumorale. Selon un autre aspect, l'invention concerne des compositions thérapeutiques à base de plaquettes et des trousses, les plaquettes portant un ou plusieurs facteurs de régulation exogènes de l'angiogenèse. L'invention concerne également des procédés permettant de moduler la libération de facteurs favorisant et inhibant l'angiogenèse par des plaquettes au moyen d'agonistes et/ou d'antagonistes de récepteurs de plaquette activés par des protéases, à savoir les récepteurs PAR-1 et PAR-4.
PCT/US2008/067592 2007-06-22 2008-06-20 Compositions thérapeutique plaquette et procédés WO2009002811A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93692107P 2007-06-22 2007-06-22
US60/936,921 2007-06-22

Publications (2)

Publication Number Publication Date
WO2009002811A2 WO2009002811A2 (fr) 2008-12-31
WO2009002811A3 true WO2009002811A3 (fr) 2009-02-12

Family

ID=39930521

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/067592 WO2009002811A2 (fr) 2007-06-22 2008-06-20 Compositions thérapeutique plaquette et procédés

Country Status (1)

Country Link
WO (1) WO2009002811A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150250822A1 (en) * 2012-10-04 2015-09-10 Genesys Research Institute Platelet compositions and uses thereof
EP3094381A4 (fr) * 2014-01-17 2017-10-25 President and Fellows of Harvard College Leurre plaquettaire et son utilisation
WO2015124570A1 (fr) * 2014-02-18 2015-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et composition pharmaceutique pour le traitement de l'infection par le virus de la grippe a
EP3143130B1 (fr) 2014-05-16 2024-03-06 Mayo Foundation for Medical Education and Research Compositions de milieux de culture cellulaire pour cellules primaires
CA3087344A1 (fr) 2018-01-05 2019-07-11 Platelet Biogenesis, Inc. Compositions et procedes pour produire des megacaryocytes
JP2021529770A (ja) * 2018-06-29 2021-11-04 プレートレット バイオジェネシス， インコーポレイテッド 薬物送達のための組成物およびその使用方法
TWI787761B (zh) * 2020-03-20 2022-12-21 台灣粒線體應用技術股份有限公司 粒線體用於促進傷口修復及/或傷口癒合之用途
WO2021231990A1 (fr) * 2020-05-15 2021-11-18 Platelet Biogenesis, Inc. Procédés et production améliorés de nouvelles plaquettes
CN119139532A (zh) * 2024-11-20 2024-12-17 昆明医科大学 一种海绵贴片及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999066923A1 (fr) * 1998-06-22 1999-12-29 Autologous Wound Therapy, Inc. Cicatrisant pour blessures ameliore a l'aide de plaquettes enrichies
US20040001816A1 (en) * 1998-06-22 2004-01-01 Cytomedix, Inc. Enriched platelet wound healant

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999066923A1 (fr) * 1998-06-22 1999-12-29 Autologous Wound Therapy, Inc. Cicatrisant pour blessures ameliore a l'aide de plaquettes enrichies
US20040001816A1 (en) * 1998-06-22 2004-01-01 Cytomedix, Inc. Enriched platelet wound healant

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ITALIANO JOSEPH ET AL: "Blood platelets organize pro- and anti-angiogenic factors into separate, distinct alpha granules: Implications for the regulation of angiogenesis", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 108, no. 11, 16 November 2006 (2006-11-16), pages 120A - 121A(Abst, XP009108492, ISSN: 0006-4971 *
MA L. ET AL.: "Proteinase-activated recepors 1 and 4 counter-regulate endostatin and VEGF release from human platelets.", PNAS, vol. 102, no. 1, 4 January 2005 (2005-01-04), pages 216 - 220, XP002503736 *
PIETRAMAGGIORI G.: "Trehalose lyophilized platelets for wound healing.", WOUND REP. REG., vol. 15, April 2007 (2007-04-01), pages 213 - 220, XP002503737 *
SALGADO R ET AL: "Platelets and vascular endothelial growth factor (VEGF): A morphological and functional study", ANGIOGENESIS, KLUWER, DORDRECHT, NL, vol. 4, 1 January 2001 (2001-01-01), pages 37 - 43, XP002995368, ISSN: 0969-6970 *

Also Published As

Publication number Publication date
WO2009002811A2 (fr) 2008-12-31

Similar Documents

Publication Publication Date Title
WO2009002811A3 (fr) Compositions thérapeutique plaquette et procédés
NZ705743A (en) Compositions and methods for treating cutaneous scarring
MX2009010067A (es) Analogos de imidazolopirimidina y su uso como inhibidores de mtor y cinasa pi3.
WO2010003120A3 (fr) Antagonistes des récepteurs de la prostaglandine d<sb>2</sb>
MX2009010132A (es) Analogos de pirazolopirimidina y su uso como inhibidores de cinasa mtor y cinasa pi3.
WO2009108720A3 (fr) Antagonistes des récepteurs d2 de la prostaglandine
WO2009108934A3 (fr) Ciments de phosphate de calcium injectables formulés avec des agents bioactifs et procédés de fabrication associés
EP2527441A3 (fr) Compositions et procédés pour traiter des tumeurs, une fibrose et une protéinose pulmonaire alvéolaire
WO2009097508A3 (fr) Procédés et compositions pour la cicatrisation
WO2012064697A3 (fr) Matières présentant des molécules de signalisation par notch pour réguler le comportement cellulaire
WO2008063291A3 (fr) Ligands polypeptidiques ciblant le cartilage et procédés d'utilisation de ceux-ci
WO2007112084A8 (fr) Procédé permettant de moduler la croissance de cellules souches hématopoïétiques
WO2010111502A3 (fr) Dispositifs médicaux comportant des particules galvaniques
GB2460597A (en) N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
WO2007038246A3 (fr) Compositions polymeres solides pour administration et methodes d'utilisation de celles-ci
WO2010037059A3 (fr) Antagonistes hétéroaryliques des récepteurs de prostaglandine d<sb>2</sb>
ATE545441T1 (de) Verfahren und vorrichtungen zur minimal invasiven abgabe von zellhaltigen fliessfähigen zusammensetzungen
MY164730A (en) Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2010057118A3 (fr) Antagonistes hétérocycliques des récepteurs de la prostaglandine d2
CL2009000246A1 (es) Compuestos derivados de 1h-imidazo[4,5-b]piridin-2-ol; moduladores de la contraccion sarcomero; composicion farmaceutica que comprende; kit farmaceutico; y uso en el tratamiento de enfermedades neuromusculares, tales como atrofia, fatiga, claudicacion, en entre otras.
MX2015000428A (es) Composiciones y metodos para regular celulas t car.
WO2010028254A3 (fr) Inhibiteurs de tyrosine kinases de récepteur de facteur de croissance de type quinazoline substituée
EP4467160A3 (fr) Formulations liquides stabilisées et lyophilisées d'adamts13
MX2021013582A (es) Composiciones que comprenden agentes biologicamente activos y sales biliares.
BRPI0507680A (pt) partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08771541

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08771541

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载